脉管复康胶囊辅助治疗急性脑梗死的临床效果

Abstract
Figure/Table
References (27)
Related Citation (15)

Download: PDF (659 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Maiguan Fukang Capsules in the adjuvant treatment of acute cerebral infarction. Methods A total of 60 patients with acute cerebral infarction admitted to the Department of Encephalopathy, Bozhou Hospital of Traditional Chinese Medicine in Anhui Province from March 2019 to November 2020 were selected. By pre-creating randomized even and odd sequences, they were divided into control group and treatment group, with 30 patients in each group. The control group was treated with Aspirin Enteric-coated Tablets, Atorvastatin Calcium Tablets and Butylphthalide Soft Capsules, and the treatment group was treated with Maiguan Fukang Capsules on the basis of the control group. The course of treatment was two weeks. The changes of clinical response rate, traditional Chinese medicine syndrome score, National Institute of Health stroke scale (NIHSS) score, activity of daily living (Barthel index), high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), angiotensin-1 (Ang-1), and homocysteine (Hcy) levels were compared between two groups before and after treatment. Adverse events during treatment were recorded in both groups. Results The clinical efficacy of the treatment group was better than that of the control group, and the difference was statistically significant (P ＜ 0.05). Before treatment, there were no significant differences in traditional Chinese medicine syndrome score, NIHSS score, Barthel index, hs-CRP, IL-6, Ang-1, and Hcy levels between the two groups (P ＞ 0.05). After treatment, traditional Chinese medicine syndrome score, NIHSS score, hs-CRP, IL-6, Ang-1, and Hcy levels in the two groups were significantly lower than before treatment, and Barthel index was significantly higher than before treatment, and traditional Chinese medicine syndrome score, NIHSS score, hs-CRP, IL-6, Ang-1, and Hcy levels in the treatment group were lower than those in the control group, the Barthel index was significantly higher than that of the control group, and the differences were highly statistically significant (P ＜ 0.01). There were no serious adverse reactions in both groups. Conclusion Maiguan Fukang Capsules has definite curative effect in the treatment of acute cerebral infarction and is worthy of clinical promotion.

Key words： Maiguan Fukang Capsules Acute cerebral infarction Angiopoietin-1 Inflammatory factor

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HE Daosheng ZHOU Hui LI Liangyong HUO Xingxing MA Kuijun▲

Cite this article:

HE Daosheng ZHOU Hui LI Liangyong HUO Xingxing MA Kuijun▲. Clinical effect of Maiguan Fukang Capsules in the adjuvant treatment of acute cerebral infarction[J]. 中国医药导报, 2022, 19(14): 60-64.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I14/60

[1] 孙翠梅，王莹，姜宏，等.急性前循环脑梗死患者血浆脂蛋白相关磷脂酶A2活性与颈内动脉狭窄的关系[J].临床神经病学杂志，2021，34（1）：28-31.
[2] 辜蕊，李蓉，唐卉，等.急性大血管闭塞性脑梗死的危险因素分析[J].临床神经病学杂志，2020，33（4）：254-258.
[3] 单晓晓，洪帮振，刘洁，等.丹参化学成分、药理作用、临床应用的研究进展及质量标志物的预测分析[J].中国中药杂志，2021，46（21）：5496-5511.
[4] 赵子樟，李佳晌，宿树兰，等.基于网络药理学及细胞实验的乳香-没药功效成分抗炎机制研究[J].中国中药杂志，2021，46（21）：5674-5682.
[5] 刘梅，郭小红，孙全，等.温郁金的化学成分和药理作用研究进展[J].现代药物与临床，2021，36（1）：204-208.
[6] 王春丽，潘春柳，姚李祥，等.鸡血藤的化学成分和药理作用研究进展[J].现代中药研究与实践，2021，35（2）：96-102.
[7] 金婷婷.丁苯酞联合脉管复康胶囊治疗急性脑梗死的疗效及机制分析[J].医学理论与实践，2021，34（21）：3726-3728.
[8] 张旭.脉管复康胶囊治疗2型糖尿病下肢病变的临床效果以及对患者微循环障碍和氧化应激损伤指标水平的影响[J].中国医药，2020，15（3）：397-400.
[9] 彭少林，杨水冰，杨井金，等.脉管复康胶囊联合甲钴胺片对糖尿病周围神经病变患者TCSS的影响及临床疗效与安全性分析[J].中国医师杂志，2019，21（3）：420-422.
[10] 彭少林，杨水冰，杨井金，等.脉管复康胶囊联合甲钴胺片对糖尿病周围神经病变患者血清Hcy、CysC、hs-CRP的影响[J].实用医学杂志，2019，35（2）：221-225.
[11] 中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志，2018，51（9）：666-682.
[12] 郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社，2002：99-105.
[13] 脑卒中患者临床神经功能缺损程度评分标准（1995）[J].中华神经科杂志，1996（6）：62-64.
[14] 李平，吴钟璇，张云如，等.中风病诊断与疗效评定标准（试行）[J].北京中医药大学学报，1996，19（1）：55-56.
[15] Pezzella FR，Picconi O，De Luca A，et al. Development of the Italian version of the National Institutes of Health Stroke Scale：It-NIHSS [J]. Stroke，2009，40（7）：2557-2559.
[16] Liu F，Tsang RC，Zhou J，et al. Relationship of Barthel Index and its Short Form with the Modified Rankin Scale in acute stroke patients [J]. J Stroke Cerebrovasc Dis，2020，29（9）：105033.
[17] Zaric BL，Obradovic M，Bajic V，et al. Homocysteine and Hyperhomocysteinaemia [J]. Curr Med Chem，2019，26（16）：2948-2961.
[18] 王莉莉，张运，贺茂林.高同型半胱氨酸血症与脑梗死复发的相关性及预测价值[J].中华老年心脑血管病杂志，2020，22（12）：1305-1307.
[19] Pan L，Yu G，Huang J，et al. Homocysteine inhibits angiogenesis through cytoskeleton remodeling [J]. Biosci Rep，2017，37（5）：BSR20170860.
[20] Pan L，Liu Z，Chen Y，et al. Angiopoietin-1：Can be produced by endothelial cells and act in an autocrine agonistic manner? [J]. Clin Hemorheol Microcirc，2020，74（3）：341-345.
[21] Yin Z，Gong G，Zhu C，et al. Angiopoietin-1 protects neurons by inhibiting autophagy after neuronal oxygen-glucose deprivation/recovery injury [J]. Neuroreport，2020， 31（11）：825-832.
[22] Yun JH，Han MH，Jeong HS，et al. Angiopoietin 1 attenuates interleukin-6-induced endothelial cell permeability through SHP-1 [J]. Biochem Biophys Res Commun，2019， 518（2）：286-293.
[23] 闫薪如，冯娟.血清血管生成素1水平与急性脑梗死发病、病情严重程度及90 d预后的关系[J].临床神经病学杂志，2016，29（2）：113-116.
[24] Teng L，Meng R. Long Non-Coding RNA MALAT1 Promotes Acute Cerebral Infarction Through miRNAs-Mediated hs-CRP Regulation [J]. J Mol Neurosci，2019，69（3）：494-504.
[25] 秦锐，谢宏斌，苏茜.神经节苷脂联合临床康复路径对急性脑梗死患者临床疗效、认知功能及神经功能的影响[J].疑难病杂志，2020，19（9）：892-895.
[26] 韩丽丽，项蓉，刘万根，等.Solitaire AB支架取栓术联合替罗非班和丁苯酞对急性脑梗死患者神经功能和炎性因子的影响[J].中国临床研究，2020，33（4）：488-492.
[27] 刘洁，胡小辉，龚道恺.急性脑梗死患者外周血Th17、Treg、Th17/Treg及炎症因子的动态变化过程研究[J].临床神经病学杂志，2020，33（2）：102-105.